Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2021-04-12 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
FORM 6-K
Foreign Filer Report
2021-04-12 English
CIRCULAR AND NOTICE OF GENERAL MEETING
Foreign Filer Report
2021-04-12 English
Proxy Form - General Meeting
Proxy Solicitation & Information Statement Classification · 98% confidence The document explicitly mentions 'General Meeting Tuesday 11 May 2021', 'EGM Proxy Form', and contains a 'Proxy Form' section with instructions on how to appoint a proxy and vote on resolutions. It also mentions a related 'Shareholder engagement event'. This material is directly related to soliciting shareholder votes and providing information ahead of a General Meeting, which aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). Although it relates to an AGM, the primary function shown here is the proxy solicitation form itself, rather than the final results (DVA) or the full meeting presentation (AGM-R).
2021-04-12 English
Circular to Shareholders and Notice of General Meeting
Proxy Solicitation & Information Statement Classification · 98% confidence The document is explicitly titled 'Circular to Shareholders and Notice of General Meeting' concerning the 'Acquisition of Alexion Pharmaceuticals, Inc. by AstraZeneca PLC'. It details the recommendation for shareholders to vote in favor of a resolution at the General Meeting, provides instructions on appointing a proxy (Form of Proxy), and references the Notice of General Meeting. This content strongly aligns with materials distributed to solicit shareholder votes and provide necessary information ahead of a general meeting, which falls under the definition of Proxy Solicitation & Information Statement (PSI). Although it mentions the proxy statement/prospectus filed with the SEC (Form F-4), the document itself is the UK Circular and Notice, making PSI the most accurate classification for this specific communication to UK shareholders regarding the vote.
2021-04-12 English
Circular and notice of general meeting
AGM Information Classification · 95% confidence The document is an RNS announcement dated April 12, 2021, regarding the 'Publication of Circular and notice of AstraZeneca General Meeting regarding the acquisition of Alexion'. It explicitly states that a Circular (which contains the notice of general meeting) has been published and provides a link to it. It also mentions that the Annual General Meeting (AGM) will take place on May 11, 2021, and encourages participation in an online shareholder engagement event related to the AGM and the acquisition. Since the document's primary function is to announce the publication of the Circular (which includes the notice for the General Meeting) and details about the upcoming AGM, it relates closely to shareholder meetings and associated documentation. The presence of the AGM date and the announcement of the Circular strongly points towards AGM-related materials. Given the options, AGM-R (AGM Information) is the most appropriate fit as it covers presentations and materials shared during the AGM, and this announcement directly relates to the upcoming AGM and the associated shareholder meeting for the acquisition approval. Although it announces a Circular, the context heavily involves the General Meeting itself.
2021-04-12 English
UPDATE ON FARXIGA COVID-19 DARE-19 PHASE III TRIAL
Foreign Filer Report
2021-04-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.